Jay Bradner

Nature Reviews Drug Discovery 16, 232 (2017). doi:10.1038/nrd.2017.50 In 2015, the haematologist Jay Bradner made the leap from supervising a few dozen researchers in his lab at the Dana-Farber Cancer Institute to overseeing more than 6,000 scientists at Novartis. As president of the Novartis Institutes for BioMedical Research (NIBR), he has now rolled out his vision for NIBR 2.0 — with an increased focus on chemical biology and open science. He spoke with Asher Mullard about his plans to restructure around emerging drug discovery tools and to forge closer ties with the rest of the scientific community.

http://feeds.nature.com/~r/nrd/rss/current/~3/g7H-3pZ629k/nrd.2017.50

Source: Nature Reviews Drug Discovery - March 30, 2017 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research